Should Tramadol Be Used in Patients with Osteoarthritis?
In this presentation, Dr. Grace Lo, M.D. discusses the benefits and risks of prescribing tramadol for use in patients with osteoarthritis. She shares details of several studies that support the use of tramadol in these patients and fields questions from participating audience members about their experiences in their own practice with this topic.
CME Credit Available
You may claim CME credit after watching this activity.
Faculty and trainees within the Department of Medicine who are involved in the care of patients need to be regularly updated with the recent advances and guidelines in the fields of medicine and quality improvement to increase clinical knowledge. This Grand Rounds series also aims to provide learners with the appropriate skills to implement the advances and guidelines in clinical practice to enhance the quality of patient care and outcomes.
At the conclusion of the session, the participants should be able to:
- Discuss the anecdotal and evidence-based benefits of Tramadol use in patients with osteoarthritis (OA).
- Examine the current FDA guidelines for use of Tramadol in rheumatology.
- Evaluate the data provided in the lecture on the use of Tramadol in OA patients.
- Medical Students
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Richard J. Hamill, M.D.
Department of Medicine
Baylor College of Medicine
Disclosure: Nothing to disclose.
Term of Approval
October 1, 2019 to October 31, 2021. Original release date: October 1, 2019.
The Office of Continuing Medical Education (OCME) makes every effort to develop CME activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical Education Standards for Commercial SupportSM, Baylor College of Medicine (BCM) has implemented a mechanism requiring everyone in a position to control the content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships: 1) at the time of the activity or within 12 months prior; and 2) of their spouses/partners.
Baylor College of Medicine does not view the existence of interests or relationships with commercial entities as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.
If at any time during this activity you feel that there has been commercial or promotional bias, please inform us by using the commercial bias comments box in the evaluation form. Please answer the questions about balance in the CME activity evaluation candidly.
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Baylor College of Medicine
Nothing to disclose.